These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34533489)

  • 21. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
    Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?
    Crapis M; Venturini S; Della Siega P; Tonizzo M; Garlatti E; Rosa R; Basso B; Pontoni E
    J Chemother; 2021 May; 33(3):174-179. PubMed ID: 32996844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
    Rodvold KA; Nicolau DP; Lodise TP; Khashab M; Noel GJ; Kahn JB; Gotfried M; Murray SA; Nicholson S; Laohavaleeson S; Tessier PR; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3294-301. PubMed ID: 19451287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.
    Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM
    J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A
    Huang H; Gao L; Engelhardt M; Saulay M; Hamed K
    Future Microbiol; 2021 Jul; 16():783-796. PubMed ID: 34155899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
    Nicholson SC; Welte T; File TM; Strauss RS; Michiels B; Kaul P; Balis D; Arbit D; Amsler K; Noel GJ
    Int J Antimicrob Agents; 2012 Mar; 39(3):240-6. PubMed ID: 22230331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
    Scheeren TWL; Welte T; Saulay M; Engelhardt M; Santerre-Henriksen A; Hamed K
    BMC Infect Dis; 2019 Feb; 19(1):195. PubMed ID: 30808293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftobiprole for the treatment of pneumonia.
    Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftobiprole: drug evaluation and place in therapy.
    Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
    Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
    Bradley JS; Ang JY; Arrieta AC; Larson KB; Rizk ML; Caro L; Yang S; Yu B; Johnson MG; Rhee EG
    Pediatr Infect Dis J; 2018 Nov; 37(11):1130-1136. PubMed ID: 30153232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.
    Mendes RE; Deshpande LM; Costello AJ; Farrell DJ; Jones RN; Flamm RK
    Microb Drug Resist; 2016 Jan; 22(1):53-8. PubMed ID: 26230870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
    Chan PLS; McFadyen L; Quaye A; Leister-Tebbe H; Hendrick VM; Hammond J; Raber S
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):551-563. PubMed ID: 33687148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftobiprole medocaril for the treatment of pneumonia.
    Hsu WH; Hsu CK; Lai CC
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):551-563. PubMed ID: 37042813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
    Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ
    Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of ceftobiprole.
    Grau S
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):34-36. PubMed ID: 31364340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.